Astellas Secures Option for Audax DAX-044 in Deal Worth Up to $1.34 Billion
Astellas Pharma entered an exclusive option and license agreement for Audax Biosciences' DAX-04.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.